Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Peter Crooks to Animals

This is a "connection" page, showing publications Peter Crooks has written about Animals.

 
Connection Strength
 
 
 
2.331
 
  1. Bowroju SK, Penthala NR, Lakkaniga NR, Balasubramaniam M, Ayyadevara S, Shmookler Reis RJ, Crooks PA. Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease. Bioorg Med Chem. 2021 09 01; 45:116311.
    View in: PubMed
    Score: 0.075
  2. Yadlapalli JSK, Albayati ZAF, Penthala NR, Hendrickson HP, Crooks PA. Stability studies of potent opioid analgesic, morphine-6-O-sulfate in various buffers and biological matrices by HPLC-DAD analysis. Biomed Chromatogr. 2017 Sep; 31(9).
    View in: PubMed
    Score: 0.056
  3. Albayati ZAF, Janganati V, Chen Z, Ponder J, Breen PJ, Jordan CT, Crooks PA. Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. Bioorg Med Chem. 2017 02 01; 25(3):1235-1241.
    View in: PubMed
    Score: 0.055
  4. Yadlapalli JSK, Ford BM, Ketkar A, Wan A, Penthala NR, Eoff RL, Prather PL, Dobretsov M, Crooks PA. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors. Pharmacol Res. 2016 11; 113(Pt A):335-347.
    View in: PubMed
    Score: 0.054
  5. Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 07 01; 26(13):2997-3000.
    View in: PubMed
    Score: 0.053
  6. Albayati ZA, Sunkara M, Schmidt-Malan SM, Karau MJ, Morris AJ, Steckelberg JM, Patel R, Breen PJ, Smeltzer MS, Taylor KG, Merten KE, Pierce WM, Crooks PA. Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1865-8.
    View in: PubMed
    Score: 0.051
  7. Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR, Crooks PA. Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. J Med Chem. 2015 Nov 25; 58(22):8896-906.
    View in: PubMed
    Score: 0.051
  8. Madadi NR, Penthala NR, Howk K, Ketkar A, Eoff RL, Borrelli MJ, Crooks PA. Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4. Eur J Med Chem. 2015 Oct 20; 103:123-32.
    View in: PubMed
    Score: 0.050
  9. Ding D, Nickell JR, Dwoskin LP, Crooks PA. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2613-6.
    View in: PubMed
    Score: 0.049
  10. Penthala NR, Bommagani S, Janganati V, MacNicol KB, Cragle CE, Madadi NR, Hardy LL, MacNicol AM, Crooks PA. Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression. Eur J Med Chem. 2014 Oct 06; 85:517-25.
    View in: PubMed
    Score: 0.047
  11. Crooks PA, Bardo MT, Dwoskin LP. Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol. 2014; 69:513-51.
    View in: PubMed
    Score: 0.045
  12. Penthala NR, Ponugoti PR, Nickell JR, Deaciuc AG, Dwoskin LP, Crooks PA. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2). Bioorg Med Chem Lett. 2013 Jun 01; 23(11):3342-5.
    View in: PubMed
    Score: 0.042
  13. Al-Ghananeem AM, Malkawi AH, Crooks PA. Bioavailability of ??-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. Drug Dev Ind Pharm. 2011 Mar; 37(3):329-34.
    View in: PubMed
    Score: 0.037
  14. Crooks PA, Zheng G, Vartak AP, Culver JP, Zheng F, Horton DB, Dwoskin LP. Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011; 11(9):1103-27.
    View in: PubMed
    Score: 0.036
  15. Zhang Z, Zheng G, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2011 Jan 01; 21(1):88-91.
    View in: PubMed
    Score: 0.036
  16. Vartak AP, Gabriela Deaciuc A, Dwoskin LP, Crooks PA. Quinlobelane: a water-soluble lobelane analogue and inhibitor of VMAT2. Bioorg Med Chem Lett. 2010 Jun 15; 20(12):3584-7.
    View in: PubMed
    Score: 0.035
  17. Zheng G, Zhang Z, Lockman PR, Geldenhuys WJ, Allen DD, Dwoskin LP, Crooks PA. Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter. Bioorg Med Chem Lett. 2010 Jun 01; 20(11):3208-10.
    View in: PubMed
    Score: 0.035
  18. Matharu J, Oki J, Worthen DR, Smith QR, Crooks PA. Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier. Bioorg Med Chem Lett. 2010 Jun 15; 20(12):3688-91.
    View in: PubMed
    Score: 0.035
  19. Yerramreddy TR, Milewski M, Penthala NR, Stinchcomb AL, Crooks PA. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery. Bioorg Med Chem Lett. 2010 Jun 01; 20(11):3280-3.
    View in: PubMed
    Score: 0.035
  20. Thirupathi Reddy Y, Narsimha Reddy P, Koduru S, Damodaran C, Crooks PA. Aplysinopsin analogs: Synthesis and anti-proliferative activity of substituted (Z)-5-(N-benzylindol-3-ylmethylene)imidazolidine-2,4-diones. Bioorg Med Chem. 2010 May 15; 18(10):3570-4.
    View in: PubMed
    Score: 0.034
  21. Zhang Z, Pivavarchyk M, Subramanian KL, Deaciuc AG, Dwoskin LP, Crooks PA. Novel bis-2,2,6,6-tetramethylpiperidine (bis-TMP) and bis-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2010 Feb 15; 20(4):1420-3.
    View in: PubMed
    Score: 0.034
  22. Hojahmat M, Horton DB, Norrholm SD, Miller DK, Grinevich VP, Deaciuc AG, Dwoskin LP, Crooks PA. Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorg Med Chem. 2010 Jan 15; 18(2):640-9.
    View in: PubMed
    Score: 0.034
  23. Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Stereocontrolled synthesis and pharmacological evaluation of cis-2,6-diphenethyl-1-azabicyclo[2.2.2]octanes as lobelane analogues. J Org Chem. 2009 Aug 21; 74(16):6072-6.
    View in: PubMed
    Score: 0.033
  24. Worthen DR, Bence AK, Stables JP, Crooks PA. In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity. Bioorg Med Chem Lett. 2009 Sep 01; 19(17):5012-5.
    View in: PubMed
    Score: 0.033
  25. Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett. 2009 Aug 01; 19(15):4346-9.
    View in: PubMed
    Score: 0.032
  26. Zheng F, McConnell MJ, Zhan CG, Dwoskin LP, Crooks PA. QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum. Bioorg Med Chem. 2009 Jul 01; 17(13):4477-85.
    View in: PubMed
    Score: 0.032
  27. Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA. Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the alpha4beta2* nicotinic acetylcholine receptor. J Enzyme Inhib Med Chem. 2009 Feb; 24(1):157-68.
    View in: PubMed
    Score: 0.032
  28. Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang Z, Bardo MT, Crooks PA. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr Symp Motiv. 2009; 55:31-63.
    View in: PubMed
    Score: 0.032
  29. Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2008 Dec 15; 18(24):6509-12.
    View in: PubMed
    Score: 0.031
  30. Albayati ZA, Dwoskin LP, Crooks PA. Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metab Dispos. 2008 Oct; 36(10):2024-9.
    View in: PubMed
    Score: 0.031
  31. Malkawi AH, Al-Ghananeem AM, Crooks PA. Development of a GC-MS assay for the determination of fentanyl pharmacokinetics in rabbit plasma after sublingual spray delivery. AAPS J. 2008 Jun; 10(2):261-7.
    View in: PubMed
    Score: 0.030
  32. Zheng G, Sumithran SP, Deaciuc AG, Dwoskin LP, Crooks PA. Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6701-6.
    View in: PubMed
    Score: 0.029
  33. Zheng G, Zhang Z, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6734-8.
    View in: PubMed
    Score: 0.029
  34. Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman P, Papke RL, Bardo MT, Crooks PA. Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochem Pharmacol. 2007 Oct 15; 74(8):1271-82.
    View in: PubMed
    Score: 0.029
  35. Al-Ghananeem AM, Malkawi AH, Crooks PA. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. Drug Dev Ind Pharm. 2007 May; 33(5):577-82.
    View in: PubMed
    Score: 0.028
  36. Al-Ghananeem AM, Crooks PA. Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules. 2007 Mar 08; 12(3):373-88.
    View in: PubMed
    Score: 0.028
  37. Al-Ghananeem AM, Albayati ZF, Malkawi A, Sonar VN, Freeman ML, Crooks PA. A pharmacokinetic study on Z-(+/-)-2-(1-benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol; a novel radio-sensitization agent. Cancer Chemother Pharmacol. 2007 Nov; 60(6):915-9.
    View in: PubMed
    Score: 0.028
  38. Zheng G, Dwoskin LP, Crooks PA. Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 2006 Nov 10; 8(4):E682-92.
    View in: PubMed
    Score: 0.027
  39. Al-Ghananeem AM, Malkawi AH, Crooks PA. Effect of pH on sublingual absorption of oxycodone hydrochloride. AAPS PharmSciTech. 2006 Mar 10; 7(1):E23.
    View in: PubMed
    Score: 0.026
  40. Howard-Sparks M, Al-Ghananeem AM, Pearson AP, Crooks PA. Evaluation of O(3alpha)-, O(21)-di-(N(1)-methyloxycarbonyl-2, 4-dioxo-5-fluoropyrimidinyl) 17alpha-hydroxy-5beta-pregnan-20-one as a novel potential antiangiogenic codrug. J Enzyme Inhib Med Chem. 2005 Oct; 20(5):417-28.
    View in: PubMed
    Score: 0.025
  41. Papke RL, Zheng G, Horenstein NA, Dwoskin LP, Crooks PA. The characterization of a novel rigid nicotine analog with alpha7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion. Bioorg Med Chem Lett. 2005 Sep 01; 15(17):3874-80.
    View in: PubMed
    Score: 0.025
  42. Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem. 2005 Aug 25; 48(17):5551-60.
    View in: PubMed
    Score: 0.025
  43. Zheng G, Dwoskin LP, Deaciuc AG, Zhu J, Jones MD, Crooks PA. Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorg Med Chem. 2005 Jun 02; 13(12):3899-909.
    View in: PubMed
    Score: 0.025
  44. Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett. 2004 Apr 19; 14(8):1863-7.
    View in: PubMed
    Score: 0.023
  45. Crooks PA, Ayers JT, Xu R, Sumithran SP, Grinevich VP, Wilkins LH, Deaciuc AG, Allen DD, Dwoskin LP. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2004 Apr 19; 14(8):1869-74.
    View in: PubMed
    Score: 0.023
  46. Chandler CM, Nickell JR, George Wilson A, Culver JP, Crooks PA, Bardo MT, Dwoskin LP. Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats. Biochem Pharmacol. 2024 10; 228:116189.
    View in: PubMed
    Score: 0.023
  47. Gali-Muhtasib HU, Abou Kheir WG, Kheir LA, Darwiche N, Crooks PA. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs. 2004 Apr; 15(4):389-99.
    View in: PubMed
    Score: 0.023
  48. Bence AK, Crooks PA. The mechanism of L-canavanine cytotoxicity: arginyl tRNA synthetase as a novel target for anticancer drug discovery. J Enzyme Inhib Med Chem. 2003 Oct; 18(5):383-94.
    View in: PubMed
    Score: 0.022
  49. Bence AK, Worthen DR, Stables JP, Crooks PA. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacol Biochem Behav. 2003 Feb; 74(3):771-5.
    View in: PubMed
    Score: 0.021
  50. Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin LP. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. J Pharmacol Exp Ther. 2019 11; 371(2):526-543.
    View in: PubMed
    Score: 0.016
  51. Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with ?9-Tetrahydrocannabinol and JWH-018. J Pharmacol Exp Ther. 2019 05; 369(2):259-269.
    View in: PubMed
    Score: 0.016
  52. Maggio SE, Saunders MA, Nixon K, Prendergast MA, Zheng G, Crooks PA, Dwoskin LP, Bell RL, Bardo MT. An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic a6?2* antagonist r-bPiDI. Drug Alcohol Depend. 2018 12 01; 193:154-161.
    View in: PubMed
    Score: 0.016
  53. Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M. Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome? Neurosci Lett. 2018 04 23; 673:24-27.
    View in: PubMed
    Score: 0.015
  54. Lee NR, Zheng G, Crooks PA, Bardo MT, Dwoskin LP. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders. AAPS J. 2018 02 09; 20(2):29.
    View in: PubMed
    Score: 0.015
  55. Kangiser MM, Dwoskin LP, Zheng G, Crooks PA, Stairs DJ. Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats. Behav Pharmacol. 2018 02; 29(1):87-97.
    View in: PubMed
    Score: 0.015
  56. Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M. Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. Life Sci. 2018 Jan 01; 192:151-159.
    View in: PubMed
    Score: 0.015
  57. Yadlapalli JSK, Dogra N, Walbaum AW, Wessinger WD, Prather PL, Crooks PA, Dobretsov M. Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats. Anesth Analg. 2017 09; 125(3):1021-1031.
    View in: PubMed
    Score: 0.014
  58. Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15; 795:143-149.
    View in: PubMed
    Score: 0.014
  59. Penthala NR, Janganati V, Alpe TL, Apana SM, Berridge MS, Crooks PA, Borrelli MJ. N-[11CH3]Dimethylaminoparthenolide (DMAPT) uptake into orthotopic 9LSF glioblastoma tumors in the rat. Bioorg Med Chem Lett. 2016 12 15; 26(24):5883-5886.
    View in: PubMed
    Score: 0.014
  60. Sau A, Lau R, Cabrita MA, Nolan E, Crooks PA, Visvader JE, Pratt MA. Persistent Activation of NF-?B in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage. Cell Stem Cell. 2016 07 07; 19(1):52-65.
    View in: PubMed
    Score: 0.013
  61. Holt JC, Kewin K, Jordan PM, Cameron P, Klapczynski M, McIntosh JM, Crooks PA, Dwoskin LP, Lysakowski A. Pharmacologically distinct nicotinic acetylcholine receptors drive efferent-mediated excitation in calyx-bearing vestibular afferents. J Neurosci. 2015 Feb 25; 35(8):3625-43.
    View in: PubMed
    Score: 0.012
  62. Jang DS, Penthala NR, Apostolov EO, Wang X, Crooks PA, Basnakian AG. Novel cytoprotective inhibitors for apoptotic endonuclease G. DNA Cell Biol. 2015 Feb; 34(2):92-100.
    View in: PubMed
    Score: 0.012
  63. Jang DS, Penthala NR, Apostolov EO, Wang X, Fahmi T, Crooks PA, Basnakian AG. Novel high-throughput deoxyribonuclease 1 assay. J Biomol Screen. 2015 Feb; 20(2):202-11.
    View in: PubMed
    Score: 0.012
  64. Sekhar KR, Benamar M, Venkateswaran A, Sasi S, Penthala NR, Crooks PA, Hann SR, Geng L, Balusu R, Abbas T, Freeman ML. Targeting nucleophosmin 1 represents a rational strategy for radiation sensitization. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1106-1114.
    View in: PubMed
    Score: 0.012
  65. Venkateswaran A, Sekhar KR, Levic DS, Melville DB, Clark TA, Rybski WM, Walsh AJ, Skala MC, Crooks PA, Knapik EW, Freeman ML. The NADH oxidase ENOX1, a critical mediator of endothelial cell radiosensitization, is crucial for vascular development. Cancer Res. 2014 Jan 01; 74(1):38-43.
    View in: PubMed
    Score: 0.011
  66. Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, Noel T, Holley AK, Zhao Y, Kiningham KK, Clair DK, Clair WH. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res. 2013 Jul 15; 73(14):4406-17.
    View in: PubMed
    Score: 0.011
  67. Yip-Schneider MT, Wu H, Stantz K, Agaram N, Crooks PA, Schmidt CM. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17; 13:194.
    View in: PubMed
    Score: 0.011
  68. Yip-Schneider MT, Wu H, Hruban RH, Lowy AM, Crooks PA, Schmidt CM. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Pancreas. 2013 Jan; 42(1):160-7.
    View in: PubMed
    Score: 0.010
  69. Adeneye Adejuwon A, Crooks PA, Fadhel-Albayati Z, Miller AF, Zito SW, Adeyemi OO, Agbaje EO. Antihyperglycemic profile of erinidine isolated from Hunteria umbellata seed. Afr J Tradit Complement Altern Med. 2013; 10(2):189-202.
    View in: PubMed
    Score: 0.010
  70. Barron S, Lewis B, Wellmann K, Carter M, Farook J, Ring J, Rogers DT, Holley R, Crooks P, Littleton J. Polyamine modulation of NMDARs as a mechanism to reduce effects of alcohol dependence. Recent Pat CNS Drug Discov. 2012 Aug; 7(2):129-44.
    View in: PubMed
    Score: 0.010
  71. Alvers KM, Beckmann JS, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology (Berl). 2012 Nov; 224(2):255-62.
    View in: PubMed
    Score: 0.010
  72. Holcomb BK, Yip-Schneider MT, Waters JA, Beane JD, Crooks PA, Schmidt CM. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. J Gastrointest Surg. 2012 Jul; 16(7):1333-40.
    View in: PubMed
    Score: 0.010
  73. Wala EP, Crooks PA, McIntosh JM, Holtman JR. Novel small molecule a9a10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats. Anesth Analg. 2012 Sep; 115(3):713-20.
    View in: PubMed
    Score: 0.010
  74. Estabrook NC, Chin-Sinex H, Borgmann AJ, Dhaemers RM, Shapiro RH, Gilley D, Huda N, Crooks P, Sweeney C, Mendonca MS. Inhibition of NF-?B and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radic Biol Med. 2011 Dec 15; 51(12):2249-58.
    View in: PubMed
    Score: 0.010
  75. Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology (Berl). 2012 Mar; 220(2):395-403.
    View in: PubMed
    Score: 0.010
  76. Holtman JR, Dwoskin LP, Dowell C, Wala EP, Zhang Z, Crooks PA, McIntosh JM. The novel small molecule a9a10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic. Eur J Pharmacol. 2011 Nov 30; 670(2-3):500-8.
    View in: PubMed
    Score: 0.010
  77. Sekhar KR, Reddy YT, Reddy PN, Crooks PA, Venkateswaran A, McDonald WH, Geng L, Sasi S, Van Der Waal RP, Roti JL, Salleng KJ, Rachakonda G, Freeman ML. The novel chemical entity YTR107 inhibits recruitment of nucleophosmin to sites of DNA damage, suppressing repair of DNA double-strand breaks and enhancing radiosensitization. Clin Cancer Res. 2011 Oct 15; 17(20):6490-9.
    View in: PubMed
    Score: 0.009
  78. Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther. 2011 Oct; 339(1):286-97.
    View in: PubMed
    Score: 0.009
  79. Vijaya Laxmi S, Thirupathi Reddy Y, Suresh Kuarm B, Narsimha Reddy P, Crooks PA, Rajitha B. Synthesis and evaluation of chromenyl barbiturates and thiobarbiturates as potential antitubercular agents. Bioorg Med Chem Lett. 2011 Jul 15; 21(14):4329-31.
    View in: PubMed
    Score: 0.009
  80. Wooters TE, Smith AM, Pivavarchyk M, Siripurapu KB, McIntosh JM, Zhang Z, Crooks PA, Bardo MT, Dwoskin LP. bPiDI: a novel selective a6?2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol. 2011 May; 163(2):346-57.
    View in: PubMed
    Score: 0.009
  81. Pivavarchyk M, Smith AM, Zhang Z, Zhou D, Wang X, Toyooka N, Tsuneki H, Sasaoka T, McIntosh JM, Crooks PA, Dwoskin LP. Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release. Eur J Pharmacol. 2011 May 11; 658(2-3):132-9.
    View in: PubMed
    Score: 0.009
  82. Horton DB, Siripurapu KB, Norrholm SD, Culver JP, Hojahmat M, Beckmann JS, Harrod SB, Deaciuc AG, Bardo MT, Crooks PA, Dwoskin LP. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther. 2011 Mar; 336(3):940-51.
    View in: PubMed
    Score: 0.009
  83. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010 Dec 23; 116(26):5983-90.
    View in: PubMed
    Score: 0.009
  84. Nickell JR, Zheng G, Deaciuc AG, Crooks PA, Dwoskin LP. Phenyl ring-substituted lobelane analogs: inhibition of [?H]dopamine uptake at the vesicular monoamine transporter-2. J Pharmacol Exp Ther. 2011 Mar; 336(3):724-33.
    View in: PubMed
    Score: 0.009
  85. Holtman JR, Crooks PA, Johnson-Hardy J, Wala EP. Antinociceptive effects and toxicity of morphine-6-O-sulfate sodium salt in rat models of pain. Eur J Pharmacol. 2010 Dec 01; 648(1-3):87-94.
    View in: PubMed
    Score: 0.009
  86. Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, Dwoskin LP, Bardo MT. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. J Pharmacol Exp Ther. 2010 Dec; 335(3):841-51.
    View in: PubMed
    Score: 0.009
  87. Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci. 2010 Jul; 99(7):3072-80.
    View in: PubMed
    Score: 0.009
  88. Milewski M, Yerramreddy TR, Ghosh P, Crooks PA, Stinchcomb AL. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. J Control Release. 2010 Aug 17; 146(1):37-44.
    View in: PubMed
    Score: 0.009
  89. Holtman JR, Crooks PA, Johnson-Hardy JK, Wala EP. The analgesic and toxic effects of nornicotine enantiomers alone and in interaction with morphine in rodent models of acute and persistent pain. Pharmacol Biochem Behav. 2010 Jan; 94(3):352-62.
    View in: PubMed
    Score: 0.008
  90. Smith AM, Dhawan GK, Zhang Z, Siripurapu KB, Crooks PA, Dwoskin LP. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices. Biochem Pharmacol. 2009 Oct 01; 78(7):889-97.
    View in: PubMed
    Score: 0.008
  91. Kiptoo PK, Paudel KS, Hammell DC, Pinninti RR, Chen J, Crooks PA, Stinchcomb AL. Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. J Pharm Sci. 2009 Feb; 98(2):583-94.
    View in: PubMed
    Score: 0.008
  92. Holtman JR, Crooks PA, Johnson-Hardy J, Wala EP. Interaction between morphine and norketamine enantiomers in rodent models of nociception. Pharmacol Biochem Behav. 2008 Oct; 90(4):769-77.
    View in: PubMed
    Score: 0.008
  93. Holtman JR, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav. 2008 Oct; 90(4):676-85.
    View in: PubMed
    Score: 0.008
  94. Yip-Schneider MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ, Schmidt CM. Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas. 2008 Oct; 37(3):e45-53.
    View in: PubMed
    Score: 0.008
  95. Banks SL, Pinninti RR, Gill HS, Crooks PA, Prausnitz MR, Stinchcomb AL. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharm Res. 2008 Jul; 25(7):1677-85.
    View in: PubMed
    Score: 0.008
  96. Bhatti BS, Strachan JP, Breining SR, Miller CH, Tahiri P, Crooks PA, Deo N, Day CS, Caldwell WS. Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands. J Org Chem. 2008 May 02; 73(9):3497-507.
    View in: PubMed
    Score: 0.007
  97. Lockman PR, Manda VK, Geldenhuys WJ, Mittapalli RK, Thomas F, Albayati ZF, Crooks PA, Dwoskin LP, Allen DD. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier. J Pharmacol Exp Ther. 2008 Jan; 324(1):244-50.
    View in: PubMed
    Score: 0.007
  98. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007 Dec 15; 110(13):4427-35.
    View in: PubMed
    Score: 0.007
  99. Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, Bardo MT. Lobelane decreases methamphetamine self-administration in rats. Eur J Pharmacol. 2007 Sep 24; 571(1):33-8.
    View in: PubMed
    Score: 0.007
  100. Howard-Sparks M, Al-Ghananeem AM, Crooks PA, Pearson AP. A novel chemical delivery system comprising an ocular sustained release formulation of a 3alpha, 17alpha, 21-trihydroxy-5beta-pregnan-20-one-BIS-5-fluorouracil [correction of flourouracil] codrug. Drug Dev Ind Pharm. 2007 Jun; 33(6):677-82.
    View in: PubMed
    Score: 0.007
  101. Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 2007 Jun; 6(6):1736-44.
    View in: PubMed
    Score: 0.007
  102. Middleton LS, Crooks PA, Wedlund PJ, Cass WA, Dwoskin LP. Nornicotine inhibition of dopamine transporter function in striatum via nicotinic receptor activation. Synapse. 2007 Mar; 61(3):157-65.
    View in: PubMed
    Score: 0.007
  103. Huang X, Zheng F, Chen X, Crooks PA, Dwoskin LP, Zhan CG. Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions. J Med Chem. 2006 Dec 28; 49(26):7661-74.
    View in: PubMed
    Score: 0.007
  104. Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology. 2007 Mar; 52(3):755-63.
    View in: PubMed
    Score: 0.007
  105. Wilkins LH, Miller DK, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of antagonists at alpha 4 beta 2* nicotinic acetylcholine receptors: inhibition of S(-)-nicotine-evoked 86Rb+ efflux from rat thalamic synaptosomes. AAPS J. 2006 Jan 13; 7(4):E922-30.
    View in: PubMed
    Score: 0.006
  106. Paudel KS, Nalluri BN, Hammell DC, Valiveti S, Kiptoo P, Hamad MO, Crooks PA, Stinchcomb AL. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. J Pharm Sci. 2005 Sep; 94(9):1965-75.
    View in: PubMed
    Score: 0.006
  107. Sumithran SP, Crooks PA, Xu R, Zhu J, Deaciuc AG, Wilkins LH, Dwoskin LP. Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity. AAPS J. 2005 Aug 29; 7(1):E201-17.
    View in: PubMed
    Score: 0.006
  108. Geldenhuys WJ, Lockman PR, Nguyen TH, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg Med Chem. 2005 Jul 01; 13(13):4253-61.
    View in: PubMed
    Score: 0.006
  109. Valiveti S, Paudel KS, Hammell DC, Hamad MO, Chen J, Crooks PA, Stinchcomb AL. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. Pharm Res. 2005 Jun; 22(6):981-9.
    View in: PubMed
    Score: 0.006
  110. Valiveti S, Hammell DC, Paudel KS, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. J Control Release. 2005 Feb 02; 102(2):509-20.
    View in: PubMed
    Score: 0.006
  111. Sekhar KR, Crooks PA, Sonar VN, Friedman DB, Chan JY, Meredith MJ, Starnes JH, Kelton KR, Summar SR, Sasi S, Freeman ML. NADPH oxidase activity is essential for Keap1/Nrf2-mediated induction of GCLC in response to 2-indol-3-yl-methylenequinuclidin-3-ols. Cancer Res. 2003 Sep 01; 63(17):5636-45.
    View in: PubMed
    Score: 0.005
  112. Grinevich VP, Crooks PA, Sumithran SP, Haubner AJ, Ayers JT, Dwoskin LP. N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther. 2003 Sep; 306(3):1011-20.
    View in: PubMed
    Score: 0.005
  113. Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors. J Pharmacol Exp Ther. 2003 Jan; 304(1):400-10.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.